ASX ANNOUNCEMENT

9 November 2026

EXPANSION OF U.S. PHASE 2B CLINICAL TRIAL CONTRACT

Highlights:

- **Contract amendment executed** to expand the Company's U.S. Phase 2b clinical trial contract from 30 to 45 investigational sites.
- **Incremental contract value of US$0.24 million (approximately A$0.34 million)**, a 33% increase on the original contract, lifting total contract value to US$0.95 million (approximately A$1.36 million).
- **15 additional SphygmoCor® XCEL systems and 30 Oscar 2 ABPM systems** to be deployed for approximately seven months, together with additional training, technical support and data management services.
- **30% initiation fee payable on execution**, with the balance invoiced monthly over the extended lease period.

CONNEQT Health Limited (ASX: CQT) ("CONNEQT" or "the Company") is pleased to announce that its wholly owned subsidiary, ATCOR Medical, Inc., has executed an amendment to expand its Phase 2b clinical trial contract with a privately owned U.S.-based biopharmaceutical company focused on developing therapies for the treatment of hypertension and other serious cardiovascular diseases (refer ASX announcement of 28 October 2025).

Contract Amendment Overview

The amendment expands the trial from 30 to 45 investigational sites across the United States and reflects the addition of a second study visit to the trial protocol.

Under the amendment, CONNEQT will provide 15 additional SphygmoCor® XCEL systems and 30 additional Oscar 2 ABPM systems. The additional equipment will be leased for approximately seven months. The Company will also provide equipment configuration, virtual operator training and certification, ongoing technical support, and data management services.

Financial Terms

The amendment has an incremental value of US$0.24 million (approximately A$0.34 million), inclusive of equipment leasing, operational support and data management services. This lifts the total contract value to US$0.95 million (approximately A$1.36 million), a 33% increase on the original contract value of US$0.72 million.

A non-refundable initiation fee of 30% of the amendment value is payable on execution, with equipment lease and other ongoing charges invoiced monthly. Unit pricing and all other terms are unchanged from the original contract, including confidentiality and termination provisions customary in agreements of this type. Revenue will be recognised progressively over the duration of the trial.

Craig Cooper, CEO, CONNEQT Health commented:

> *"The expansion of this trial from 30 to 45 sites is a strong endorsement of our team's delivery and of SphygmoCor's role in generating reliable cardiovascular endpoints. It reflects the growing demand from pharmaceutical sponsors for our vascular assessment platforms and services."*

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations
Ben Henri
ben.henri@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").